SLRN
Acelyrin, Inc. (SLRN) 10Y Growth Potential Analysis (2026)
Revenue Growth
0No revenue growth evidence in the provided metrics; revenue per share is 0 and price-to-sales is 0, indicating no demonstrated sales base in the dataset.
Profitability
0Margins are all 0.0% in the provided ratios, while ROA (-50.5%), ROE (-44.5%), and ROIC (-68.1%) are deeply negative, showing no current profitability.
Cash Flow
0Operating cash flow and free cash flow are negative, with FCF per share at -3.07 and FCF yield at -1.33%, indicating ongoing cash burn.
Balance Sheet
0Liquidity is strong with a current ratio of 18.1 and cash per share of 4.51, but the solvency ratio is negative and the business remains loss-making.
Reinvestment
0Capex is minimal relative to operating cash flow, but the company is not generating positive operating cash flow to reinvest from.
Moat
0No evidence of pricing power or durable operating advantage is visible in the provided metrics, with zero margins and negative returns on capital.
Valuation
0Traditional valuation multiples are not meaningful here because sales and earnings are not positive; the stock trades below book value at 0.49x P/B.
Shareholder Returns
0No dividend is being paid and there is no evidence of buybacks or other shareholder return programs in the provided data.
Risk
0The main risks are persistent losses, negative cash flow, and dependence on a strong cash balance rather than operating performance.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Acelyrin, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.